<i>JAK2</i> is a critical therapeutic target in <scp>VEXAS</scp> syndrome treated with ruxolitinibAndrea Ceccardi, Gabriele Zoppoli, Andrea Bellodi et al.|British Journal of Haematology|2025Cited by 8